Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Associations of endpoints with SNP CYP19A1 rs10046 variants, overall and according to treatment assignments

From: Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

   CYP19A1: rs10046
Endpoint Cohort T/T vs T/C, C/C patients (events) Univariate model OR (95 % CI)a Univariate model Interaction P valueb Multivariable model OR (95 % CI)c
Hot flashes/sweating All patients 446 (172) vs 1519 (676) 0.78 (0.63, 0.97) 0.03 0.83 (0.66, 1.03)
Exemestane + OFS 227 (77) vs 759 (334) 0.65 (0.48, 0.89) 0.67 (0.49, 0.93)
Tamoxifen + OFS 219 (95) vs 760 (342) 0.94 (0.69, 1.27) 1.04 (0.75, 1.43)
Musculoskeletal events All patients 446 (110) vs 1520 (406) 0.90 (0.70, 1.15) 0.39 0.85 (0.66, 1.1)
Exemestane + OFS 227 (75) vs 759 (256) 0.97 (0.71, 1.33) 0.96 (0.69, 1.32)
Tamoxifen + OFS 219 (35) vs 761 (150) 0.77 (0.52, 1.16) 0.77 (0.51, 1.17)
  1. aEstimates from univariate logistic regression model. b P value from test of rs10046 variants ((T/T) vs. T/C, C/C) by treatment interaction in logistic regression model (univariable) assessing association between the SNP variants and early-onset adverse events in the overall cohort. cAdjusted for baseline characteristics: age, menstrual status, body mass index, adjuvant chemotherapy use, treatment assignment (for “all patients” cohort), baseline hot flashes/sweating or baseline musculoskeletal symptoms (according to endpoint) and prior to or baseline concomitant medications use and use during relevant time period for the endpoint (yes or no). SNP single nucleotide polymorphism, OFS ovarian function suppression, OR odds ratio, CI confidence interval